Publication: Initial treatment response in ocular myasthenia gravis: A comparison between low and moderate doses of prednisolone
Issued Date
2020-01-01
Resource Type
ISSN
11775483
11775467
11775467
Other identifier(s)
2-s2.0-85088278426
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Ophthalmology. Vol.14, (2020), 2051-2056
Suggested Citation
Thanatporn Threetong, Anuchit Poonyathalang, Pisit Preechawat, Panitha Jindahra, Tanyatuth Padungkiatsagul, Kavin Vanikieti Initial treatment response in ocular myasthenia gravis: A comparison between low and moderate doses of prednisolone. Clinical Ophthalmology. Vol.14, (2020), 2051-2056. doi:10.2147/OPTH.S261259 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58275
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Initial treatment response in ocular myasthenia gravis: A comparison between low and moderate doses of prednisolone
Other Contributor(s)
Abstract
© 2020 Threetong et al. Purpose: To evaluate the initial treatment response to low doses of prednisolone, compared with moderate doses, in ocular myasthenia gravis (OMG). Patients and Methods: A retrospective chart review of patients with adult-onset (age ≥15 years old) OMG, who were treated with prednisolone, was conducted. Subjects were divided into two groups according to their prednisolone dosing regimen. The low-dose group was defined as those with an average 12-week cumulative dose of prednisolone <0.435 mg/ kg/day and the moderate-dose group averaged 0.435–1.000 mg/kg/day. The primary outcome of interest was the comparison of clinical response to prednisolone at 12 weeks between the low-dose and moderate-dose groups. The secondary outcome was the difference in adverse events between treatment groups. Results: Of 34 subjects, 16 subjects (47.1%) were male. The mean age at onset was 44.0 ±18.1 years. The most common presenting ocular feature was ptosis with ophthalmoplegia (22 subjects, 64.7%), followed by isolated ptosis (nine subjects, 26.5%) and isolated ophthalmoplegia (three subjects, 8.8%). Half of the subjects were treated with low-dose prednisolone and the other half were treated with moderate-dose prednisolone. There were no substantial differences in baseline characteristics between treatment groups. After 12 weeks of treatment, nine of 17 subjects (52.9%) and 13 of 17 subjects (76.5%) in the low-and moderate-dose groups, respectively, were regarded as responsive to the prednisolone treatment (P=0.28). Adverse events were exclusively observed in the moderate-dose group. Conclusion: Treatment of OMG with an average 12-week cumulative dose of prednisolone <0.435 mg/kg/day (low dose) shows a comparable responsive outcome to 0.435–1.000 mg/ kg/day of prednisolone (moderate dose). Treating OMG with low-dose prednisolone can minimize prednisolone-related adverse events. However, a prospective randomized controlled trial with a larger study population is warranted in order to gain more insight into the proper dosage of prednisolone for OMG.